Skip to main content
. 2017 Nov 22;29(2):323–328. doi: 10.1007/s00198-017-4304-9

Table 2.

Least significant change (LSC) analysis comparing abaloparatide-SC 80 μg, teriparatide (TPTD), and placebo for two different LSC levels

At 6 months
LSC 95% ABL-SC 80 μg TPTD Placebo
Significant individual gain (%) + 4.20 52.2* 30.0 10.3
Significant individual loss (%) − 4.20 0.0¥ 6.7 17.2

ABL-SC abaloparatide-SC, LSC least significant change, TPTD teriparatide

*p = 0.001 versus placebo

p = 0.06 versus placebo

¥ p = 0.05 versus placebo